AFF family genes (AFF1, AFF2, AFF3, AFF4, AFFs) are closely related to the occurrence, development and prognosis of a variety of tumors, but the relationship between AFFs and acute myeloid leukemia (AML) is still unclear. This study aims to explore the relationship between AFFs and the prognosis of AML by bioinformatics and real time quantitative PCR.
Analyze the expression of AFFs in AML patients and AML cell lines through ONCOMINE, GEPIA, EMBL-EBI, and CCLE databases, explore the prognostic value of AFFs in AML through the TCGA database,explore Co-expression and functional enrichment analysis of AFFs through the Linkedomics, DAVID and KOBAS database.We collected peripheral blood samples of 24 cases of AML (non-M3 subtype) and 8 cases of benign individuals, and detected the mRNA expression level of AFFs by real-time fluorescent quantitative PCR (clinical data comes from hospitalized medical records).
The results of multiple data sets showed that the mRNA transcription level of AFF1, AFF2, AFF3, and AFF4 in AML was significantly higher than that of normal people. Among them, the high expression of AFF1, AFF2, and AFF3 was statistically significant (p<0.05). Our clinical data showed that the mRNA expression levels of AFF1 and AFF2 in AML patients were higher than those in the control group (p<0.05). The high expression of AFF1 was significantly negatively correlated with overall survival (OS) (p<0.05), the high expression of AFF2 was significantly positively correlated with OS (p<0.05), and the high expression of AFF3 was not correlated with OS (p>0.05).
AFF1 and AFF2 are highly expressed in AML. The high expression of AFF1 is significantly negatively correlated with OS, and the high expression of AFF2 is significantly positively correlated with OS, which may become a new target for treatment.